AbbVie (ABBV) EPS (Basic) Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Basic) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
77.05% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
320.46% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-14.12% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-21.17% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.65% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
44.22% |
| Dec 31, 2025 |
-9.80% |
| Sep 30, 2025 |
-64.42% |
| Jun 30, 2025 |
0.00% |
| Mar 31, 2025 |
-34.14% |
| Dec 31, 2024 |
-26.18% |
| Sep 30, 2024 |
-20.93% |
| Jun 30, 2024 |
22.39% |
| Mar 31, 2024 |
-27.25% |
| Dec 31, 2023 |
258.30% |
| Sep 30, 2023 |
-8.37% |
| Jun 30, 2023 |
64.83% |
| Mar 31, 2023 |
-59.93% |
| Dec 31, 2022 |
-9.58% |
| Sep 30, 2022 |
20.46% |
| Jun 30, 2022 |
2.00% |
| Mar 31, 2022 |
15.16% |
| Dec 31, 2021 |
56.67% |
| Sep 30, 2021 |
-0.56% |
| Jun 30, 2021 |
-30.66% |
| Mar 31, 2021 |
4.75% |
| Dec 31, 2020 |
-30.66% |
| Sep 30, 2020 |
8.42% |
| Jun 30, 2020 |
-33.58% |
| Mar 31, 2020 |
23.59% |
| Dec 31, 2019 |
29.78% |
| Sep 30, 2019 |
9.40% |
| Jun 30, 2019 |
-20.90% |
| Mar 31, 2019 |
25.74% |
| Dec 31, 2018 |
-49.22% |
| Sep 30, 2018 |
34.13% |
| Jun 30, 2018 |
14.47% |
| Mar 31, 2018 |
39.57% |
| Dec 31, 2017 |
27.22% |
| Sep 30, 2017 |
47.17% |
| Jun 30, 2017 |
20.26% |
| Mar 31, 2017 |
20.60% |
| Dec 31, 2016 |
7.10% |
| Sep 30, 2016 |
17.37% |
| Jun 30, 2016 |
13.90% |
| Mar 31, 2016 |
10.81% |
| Dec 31, 2015 |
-1.73% |
| Sep 30, 2015 |
-9.44% |
| Jun 30, 2015 |
1.64% |
| Mar 31, 2015 |
4.55% |